The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data

Bo Li | Aixia Liu | Yi Wen | Guang Yang | Jing Zhao | Xiaohan Li | Yuanli Mao | Boan Li

Department of Clinical Laboratory, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

Correspondence
Boan Li and Yuanli Mao, Department of Clinical Laboratory, The Fifth Medical Centre of PLA General Hospital, Beijing 100039, China. Emails: lba@263.net (BL); maoyuanlee@163.com (YM)

Funding information
National key S&T Special Projects in China, Grant/Award Number: 2017ZX10302201-001-006; Capital Characteristic Clinic Project in China, Grant/Award Number: Z171100001017180

Abstract

Background and aims: Hepatocellular carcinoma (HCC) is one of the most common malignancy with poor prognosis, and the mortality rate remains high. More than 70% of HCC patients have recurrence within 5 years after treatment. The purpose of this study is to evaluate the prognostic values of serum markers with retrospective data.

Methods: We applied real-world data (RWD) to analyze the prognostic values of six serum markers for HCC patients after treatment, including α-fetoprotein (AFP), α-fetoprotein-L3 (AFP-L3), Golgi protein73 (GP73), alanine aminotransferase (ALT), albumin (ALB), and total bilirubin (TBil). A total of 268 cases were enrolled to analyze recurrence-free survival (RFS), and 104 cases were used to analyze overall survival (OS).

Results: Our results demonstrated that patients with higher AFP and AFP-L3 had shorter RFS (p = 0.016 and 0.004), while higher GP73, ALT, and TBil experienced longer RFS (p = 0.000, 0.020, and 0.019). Patients with high-level GP73, ALT, TBil, and low-level ALB had significantly higher mortality rate (p=0.035, 0.008, 0.010, and 0.005). Multivariate analysis revealed that GP73 (HR = 1.548, p = 0.001) and ALT (HR = 1.316, p = 0.046) were identified as independent prognostic factors for RFS, ALB (HR = 0.127, p = 0.007), and ALT (HR = 0.237, p = 0.01) were identified as independent prognostic factors for OS. Subgroups analysis showed that GP73 had better prognostic values than other serum markers in early-stage HCC (p = 0.023).

Conclusions: Our study demonstrates that AFP, AFP-L3, and GP73 can be used as prognostic indicators for predicting the recurrence of HCC, while liver function tests have better survival prediction values. GP73 can act as a promising prognostic marker for early-stage HCC.

KEYWORDS
hepatocellular carcinoma, overall survival, real-world data, recurrence-free survival, tumor biomarkers

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. In 2018, a Cancer Journal for Clinicians had published the latest global cancer report which revealed that the morbidity and mortality of liver cancer were sixth and fourth, respectively, in all malignant tumors. Approximately 800,000 patients develop liver cancer and 780,000 patients die of it in the world each year. Among these liver cancer patients, 75%–85% of them are HCC cases. HCC also has high death rate and was difficult to be cured, and the median survival time of HCC population was less than 10 months and overall 5-year survival rate less than 20%.  

At present, several therapeutic methods are available to treat HCC, including surgical resection, interventional therapy, cryoablation, and radiofrequency ablation, etc. However, no matter what methods are applied, recurrence will happen after treatment and leading to treatment failure. Previous studies have reported that more than 70% of patients who underwent invasive therapies had HCC recurrence within 5 years, and most recurrences occurred because of dissemination of primary tumor. Therefore, the therapeutic effect of HCC is still far from optimistic currently. HCC recurrence is a main obstruction for the improvement in long-term survival rate of HCC patients.

Various prognostic biomarkers have been developed during the past decades to predict the clinical outcomes of HCC patients. American Association for the Study of Liver Diseases (AASLD) once recommended imaging techniques, and α-fetoprotein (AFP) test were used as monitoring methods for HCC recurrence. However, imaging techniques are costly and time-consuming. AASLD guideline indicated that the re-elevation of serum level of AFP after treatment is associated with recurrence and poor outcomes. Compared with imaging techniques, serum marker detection is more rapid and cost-effective. Except for AFP, other biomarkers such as α-fetoprotein-L3 (AFP-L3) and Golgi protein73 (GP73) are also regarded as potential prognostic biomarkers and are applied broadly at present. In addition, liver function tests, including alanine aminotransferase (ALT), albumin (ALB), and total bilirubin (TBil), have also shown prognostic values in clinical practice.

However, large-scaled population-based investigations about prognostic biomarkers in HCC are absent till now due to difficult longer-term follow-up. Hence, in this study we applied real-world data (RWD) to analyze the prognostic values of serum markers in HCC. RDW is defined as data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. All the data collected in this study were derived from the electronic medical record (EMR). Compared with trial data, RDW not only can evaluate the clinical values in a more realistic way but also can avoid longer-term follow-up process.

## Materials and Methods

### Subjects

We searched for potentially eligible patients using the EMR system of our hospital from January 2013 to January 2019. All included subjects were HCC patients with invasive therapies, and the medical records were tracked for five years subsequently. The data were collected for further analysis if the definite outcomes (recurrence or death) were acquired. The HCC diagnosis was confirmed by MRI based on guidelines from ministry of health of the People's Republic of China and guideline from the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases.

### Laboratory Tests

Six routine serum markers were selected for further analysis, including three tumor biomarkers (AFP, AFP-L3, and GP73) and three liver function tests (ALB, ALT, and TBil). These markers were compared between patients with abnormal serum levels and those with normal serum levels. The judgment criteria are as follows: AFP > 25 ng/mL, AFP-L3 > 1.0 ng/mL, GP73 > 150 ng/mL, ALB < 35 g/L, TBil > 19 μmol/L.
ALT>40 U/L. Liver function tests were detected by an automatic biochemical analyzer (AU8000, Beckman Coulter). AFP and AFP-L3 were measured by Automated Immunoassay Analyzer (COBAS6000, ROCHE). Enzyme-linked immuno-absorbent assay kits for GP73 were obtained from Hotgen Biotech. All results collected were measured within one week before treatments.

2.3 | Statistical analysis

All statistical analyses were performed using SPSS 14.0 software (SPSS, Inc.). Recurrence-free survival (RFS) was calculated by patients with definite recurrent records, and overall survival (OS) was calculated by patients with definite survival records. Survival curves were plotted by Kaplan-Meier method, and comparison between groups was analyzed by log-rank test. The Cox proportional hazard regression model was used for univariate and multivariate analyses. A value of \( p < 0.05 \) was considered to be statistically significant.

3 | RESULTS

3.1 | Clinical characteristics of included patients

Finally, a total of 3373 HCC patients were checked and 3063 of them were excluded for insufficient data or loss of follow-up. Among these collected patients, 268 cases had definite recurrent records (245 with recurrence, 23 without recurrence), 104 cases had definite survival records (15 died, 89 survived), and the search workflow is shown in Figure 1. Of the entire study population, 234 were males and 76 were females. The median age was 56 years (range 33–81 years). Seventy-three cases (23.5%) were suffered from hypertension. Sixty-five were diabetes mellitus patients (21.0%). A total of 240 (77.4%) were infected by HBV, and 62 cases (20.0%) were infected by HCV. Forty-three (13.9%) of them had alcohol intake history.

| Variables | RFS |  |  |
|-----------|-----|---|---|
|           | Median | Std.error | 95% CI | \( p \) |
|           |       |     |       |     |
| AFP(ng/mL) |       |     |       |     |
| >25       | 9     | 0.815 | 7.402-10.598 | 0.016 |
| ≤25       | 13    | 1.755 | 9.560-16.440 | 55 |
| AFP-L3(ng/mL) |       |     |       |     |
| >1.0      | 9     | 0.874 | 7.286-10.714 | 0.004 |
| ≤1.0      | 14    | 2.120 | 9.845-18.155 | 54 |
| GP73(ng/mL) |       |     |       |     |
| >150      | 13    | 1.590 | 9.884-16.16 | 0.000 |
| ≤150      | 8     | 0.642 | 6.741-9.259 | 60 |
| ALB(g/L)  |       |     |       |     |
| <35       | 10    | 1.331 | 7.391-12.609 | 0.656 |
| ≥35       | 10    | 1.029 | 7.984-12.016 | 58 |
| TBil(μmol/L) |       |     |       |     |
| >19       | 12    | 0.950 | 10.138-13.862 | 0.020 |
| ≤19       | 9     | 0.838 | 7.358-10.642 | 57 |
| ALT(U/L)  |       |     |       |     |
| >40       | 12    | 1.996 | 8.087-15.913 | 0.019 |
| ≤40       | 9     | 1.061 | 6.920-11.080 | 56 |

3.2 | Comparison of survival time in RFS and OS

Log-rank test was performed with recurrent records which demonstrated that patients with higher AFP and AFP-L3 had shorter RFS (\( p = 0.016 \) and 0.004), while those who with higher GP73, ALT, and TBil experienced longer RFS (\( p = 0.000, 0.020 \) and 0.019). The median RFS was only 9 months in high-level AFP and AFP-L3 patients. However, in low-level patients, the median RFS was 13 and 14 months, respectively. Patients with higher GP73, TBil, and ALT had longer RFS, while those with low level had shorter RFS. As regards ALB, there was no significant difference between the abnormal and normal level groups in RFS (\( p = 0.656 \)). Analysis with survival records also revealed that patients with higher GP73, ALT, TBil, and low-level ALB had significantly higher mortality rate (\( p = 0.035, 0.010, 0.008, \) and 0.005). The average survival times were 50, 47, 47, and 46 months in abnormal groups and were 60, 58, 57, and 56 months in normal group. In addition, all the patients with low-level GP73 (≤150 ng/mL) survived until the end of 5 years follow-up. However, the levels of two tumor biomarkers...
(AFP and AFP-L3) were not associated with the mortality of HCC patients ($p > 0.05$). See Table 1, Figure 2, and Figure 3.

### 3.3 | Univariate analysis and multivariate analysis for RFS and OS

Six serum markers and gender, age, tumor size, differentiation degree, metastasis, and therapeutic methods were defined as variables. A univariate analysis was conducted first, and those variables with a $p < 0.05$ were included in a multivariate analysis. In univariate analyses, low level of AFP (HR = 0.738, $p = 0.02$) and AFP-L3 (HR = 0.681, $p = 0.006$) and high level of GP73 (HR = 1.581, $p = 0.001$), ALT (HR = 1.361, $p = 0.024$), and TBil (HR = 1.341, $p = 0.025$) were significantly associated with longer RFS. Tumor size (HR = 0.271, $p = 0.013$), ALB (HR = 0.156, $p = 0.014$), ALT (HR = 0.271, $p = 0.017$), and TBil (HR = 0.213, $p = 0.016$) also showed significance with OS.

In multivariate analyses, the following two independent factors were identified for RFS, they were GP73 (HR = 1.548, $p = 0.001$) and ALT (HR = 1.316, $p = 0.046$). Tumor size (HR = 0.315, $p = 0.032$), ALB (HR = 0.127, $p = 0.007$), and ALT (HR = 0.237, $p = 0.01$) still were identified as independent prognostic factors for OS, see Table 2 and Table 3.

### 3.4 | Subgroups analysis with serum markers for RFS

In order to obtain more in-depth interpretations, we further carried out the subgroup analysis according to the tumor size and therapeutic methods in recurrent populations. We did not perform subgroup analysis in the survival population due to small sample size. We divided all recurrent records into two groups, and patients with tumor size less than 3cm were defined as early-stage tumor or else were defined as advanced stage tumor. From Table 4, we can see that recurrent time with four markers (AFP, AFP-L3, GP73, and ALT) also had significant difference in advanced stage tumor group ($p < 0.05$). However, in early-stage tumor group, only GP73 and ALT still had significant difference.

The results of subgroups analysis in therapeutic methods showed that all the serum markers had no significant differences in patients with surgical resection ($p > 0.05$). As regards interventional therapy and cryoablation, three tumor markers (AFP, AFP-L3, and GP73) also had significant differences ($p < 0.05$). For radiofrequency ablation and comprehensive therapy, there was only one significant prognostic marker ($p < 0.05$), and TBil had significant difference in radiofrequency ablation ($p = 0.008$) and ALB in comprehensive therapy ($p = 0.048$).

**FIGURE 2** Kaplan-Meier survival curves for recurrence-free survival (RFS) in HCC patients. (A and B) RFS was significantly better in low-level AFP and AFP-L3 groups than high-level groups ($p < 0.05$). (C–F) RFS was significantly better in high-level GP73, TBil, and ALT groups than low-level groups ($p < 0.05$)
DISCUSSION

Lots of attentions have been paid to the prognostic biomarkers for HCC in the past several years. New genetic detection technologies have been promising tools for potential biomarkers discovery. Cell-free DNA, lncRNA, and mRNA expression also had important prognostic value for HCC according to the previous studies.\textsuperscript{14–16} However, these genetic biomarkers are still far from being applied in clinical diagnosis due to high cost and complex manufacturing processes. Traditional routine tests still play pivotal roles in the prediction of outcomes in HCC patients at present.\textsuperscript{17–19}

In this study, we investigated the prognostic values of six serum markers in HCC populations after treatments based on RWD records. Three tumor biomarkers and three liver function tests were analyzed in RFS and OS, respectively. Wang NY et al\textsuperscript{7} evaluated prognostic values of these same three tumor biomarkers with HCC patients after radiofrequency ablation, and their results demonstrated that the short-term (6 months) recurrence rate of AFP-positive patients was obviously higher than that of AFP-negative patients, but AFP-L3 and GP73 levels were not associated with short-term recurrence. However, our results in this study showed that all these three biomarkers were strong predictors of long-term (60 months) recurrence in patients with HCC. Kim SH et al.\textsuperscript{20} obtained the similar results from HCC patients after liver transplantation. They also indicated that high level of AFP was a significant independent risk factor for recurrence, and the median time to recurrence was 10 months. Montalvá EM et al.\textsuperscript{21} followed up HCC patients after liver transplantation more than 60 months, and they found that the OS and RFS were both differed between groups when an AFP cutoff level of 1,000 ng/mL was used. We used 25ng/mL as cutoff level in this study, and RFS was also differed between groups, but OS was not (p = 0.085). AFP is still the most widely used tumor markers for HCC, and our present study and previous studies have confirmed its prognostic value in the recurrence of HCC. However, its prognostic value in survival time is still needed to be validated in the future.

GP73 is a resident Golgi-specific membrane protein expresses by biliary epithelial cells in the normal liver. Our previous studies had reported that it is superior to AFP as an early diagnostic biomarker for HCC, and serum GP73 level was significantly decreased during the progression of HCC.\textsuperscript{22,23} As a serological marker, GP73 has always been controversial. Some reports pointed out that GP73 should be an indicator of liver inflammation and fibrosis instead of a tumor marker.\textsuperscript{24–27} Some research results showed that the expression of serum GP73 was significantly higher in the HCC patients compared with the liver fibrosis and cirrhosis patients.\textsuperscript{28,29} However, there are few reports on the prognostic value of GP73 in HCC patients. In this study, we also found that GP73 was an outstanding prognostic

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Kaplan-Meier survival curves for overall survival (OS) in HCC patients. (C–F) OS was significantly better in low-level GP73, TBil, and ALT groups than high-level groups (p < 0.05). (D) OS was significantly better in high-level ALB groups than low-level groups (p < 0.05).}
\end{figure}
biomarker for recurrent and survival prediction after treatment in HCC patients. Multivariate analysis also demonstrated that GP73 was an independent adverse prognostic factor for RFS prediction. Our findings showed that patients with higher GP73 experienced longer RFS and shorter OS. Except for GP73, ALT also was proven as an independent adverse prognostic factor for RFS in our study, and patients with higher ALT had longer RFS and shorter OS. In this study, ALT and ALB were identified as independent prognostic factors for OS. Higher ALT and lower ALB indicate that liver function is damaged severely, and it is the cause of high death rate in patients. However, for the reasons of higher ALT and TBil patients had longer RFS are still unclear.

| TABLE 2 Univariate analysis and multivariate analysis for RFS |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Variables**   | **Univariate analysis** | **Multivariate analysis** |
|                 | HR     | 95% CI       | p   | HR     | 95% CI       | p   |
| Gender          |        |              |     |        |              |     |
| Male            | 1      | 0.697-1.257  | 0.659|        |              |     |
| Female          | 0.936  |              |     |        |              |     |
| Age (y)         |        |              |     |        |              |     |
| >56             | 1      | 0.691-1.142  | 0.356|        |              |     |
| ≤56             | 0.888  |              |     |        |              |     |
| Tumor Size(cm)  |        |              |     |        |              |     |
| >3              | 1      | 0.699-1.161  | 0.420|        |              |     |
| ≤3              | 0.901  |              |     |        |              |     |
| Metastasis      |        |              |     |        |              |     |
| No              | 1      | 0.934-1.710  | 0.129|        |              |     |
| Yes             | 1.264  |              |     |        |              |     |
| Differentiation |        |              |     |        |              |     |
| Low             | 1      | 0.888-1.598  | 0.244|        |              |     |
| High            | 1.191  |              |     |        |              |     |
| Therapeutic Methods |      |              |     |        |              |     |
| Resection       | 1      |              |     |        |              |     |
| Interventional therapy | 1.335 | 0.475-3.747  | 0.584|        |              |     |
| Cryoablation    | 0.940  | 0.345-2.560  | 0.904|        |              |     |
| Radiofrequency ablation | 1.337 | 0.480-3.720  | 0.578|        |              |     |
| Comprehensive therapy | 0.785 | 0.278-2.213  | 0.647|        |              |     |
| AFP(ng/mL)      |        |              |     |        |              |     |
| >25             | 1      | 0.571-0.954  | 0.02 | 1      | 0.648-1.613  | 0.924|
| ≤25             | 0.738  |              |     | 1.022  |              |     |
| AFP-L3(ng/mL)   |        |              |     |        |              |     |
| >1.0            | 1      | 0.519-0.894  | 0.006| 1      | 0.485-1.269  | 0.322|
| ≤1.0            | 0.681  |              |     | 0.784  |              |     |
| GP73(ng/mL)     |        |              |     |        |              |     |
| >150            | 1      | 1.220-2.049  | 0.001| 1      | 1.193-2.009  | 0.001|
| ≤150            | 1.581  |              |     | 1.548  |              |     |
| ALB(g/L)        |        |              |     |        |              |     |
| <35             | 1      | 0.822-1.359  | 0.666|        |              |     |
| ≥35             | 1.057  |              |     |        |              |     |
| TBil(μmol/L)    |        |              |     |        |              |     |
| >19             | 1      | 1.038-1.732  | 0.025| 1      | 0.877-1.544  | 0.294|
| ≤19             | 1.341  |              |     | 1.164  |              |     |
| ALT(U/L)        |        |              |     |        |              |     |
| >40             | 1      | 1.041-1.780  | 0.024| 1      | 1.005-1.724  | 0.046|
| ≤40             | 1.361  |              |     | 1.316  |              |     |
We also investigated the RFS of six serum markers in different stages and therapeutic methods by subgroup analysis. In advanced stage HCC, six serum markers had similar performance with overall population, but in early stage, GP73 had more superiority than other markers. This result revealed that GP73 had better prognostic value than others, particularly in early-stage HCC. Subgroup analysis in therapeutic methods also provided some new findings. Three tumor biomarkers only had significant RFS in interventional therapy and

| Variables               | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | HR 95% CI           | p                     | HR 95% CI           | p                     |
| Gender                  |                     |                       |                      |
| Male                    | 1 0.153–1.918       | 0.342                 | 1 0.109–0.906       | 0.032                 |
| Female                  | 0.541               |                       | 0.315               |
| Age (y)                 |                     |                       |                      |
| >56                     | 1 0.274–2.085       | 0.589                 | 1 0.109–0.906       | 0.032                 |
| ≤56                     | 0.756               |                       | 0.315               |
| Tumor Size(cm)          |                     |                       |                      |
| >3                      | 1 0.096–0.762       | 0.013                 | 1 0.109–0.906       | 0.032                 |
| ≤3                      | 0.271               |                       | 0.315               |
| Metastasis              |                     |                       |                      |
| No                      | 1 0.362–4.553       | 0.699                 |                      |
| Yes                     | 1.284               |                       |                      |
| Differentiation         |                     |                       |                      |
| Low                     | 1 0.050–2.897       | 0.351                 |                      |
| High                    | 0.381               |                       |                      |
| Therapeutic Methods     |                     |                       |                      |
| Resection               | 1                    |                       |                      |
| Interventional therapy  | 1.103 0.141–8.615   | 0.926                 |                      |
| Cryoablation            | 1.193 0.165–8.632   | 0.861                 |                      |
| Radiofrequency ablation | 1.249 0.164–9.501   | 0.830                 |                      |
| Comprehensive therapy   | 1.000 0.133–7.491   | 1.000                 |                      |
| AFP(ng/mL)              |                     |                       |                      |
| >25                     | 1 0.122–1.201       | 0.1                   |                      |
| ≤25                     | 0.382               |                       |                      |
| AFP-L3(ng/mL)           |                     |                       |                      |
| >1.0                    | 1 0.185–1.827       | 0.353                 |                      |
| ≤1.0                    | 0.582               |                       |                      |
| GP73(ng/mL)             |                     |                       |                      |
| >150                    | 1 0.000–5.907       | 0.198                 |                      |
| ≤150                    | 0.033               |                       |                      |
| ALB(g/L)                |                     |                       |                      |
| <35                     | 1 0.035–0.692       | 0.014                 | 1 0.028–0.570       | 0.007                 |
| ≥35                     | 0.156               | 0.127                 |                      |
| TBil(μmol/L)            |                     |                       |                      |
| >19                     | 1 0.060–0.754       | 0.016                 | 1 0.108–1.584       | 0.197                 |
| ≤19                     | 0.213               | 0.413                 |                      |
| ALT(U/L)                |                     |                       |                      |
| >40                     | 1 0.093–0.794       | 0.017                 | 1 0.079–0.710       | 0.01                  |
| ≤40                     | 0.271               | 0.237                 |                      |
| Variables     | Tumor Size | Therapeutic Methods |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|---------------|------------|---------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|               | >3 cm      | ≤3 cm               | >3 cm| ≤3 cm | >3 cm| ≤3 cm | >3 cm| ≤3 cm | >3 cm| ≤3 cm | >3 cm| ≤3 cm | >3 cm| ≤3 cm | >3 cm| ≤3 cm |
|               | Median     | p                   | Median| p     | Median| p     | Median| p     | Median| p     | Median| p     | Median| p     | Median| p     |
| AFP(ng/mL)    | >25        | 8                   | 0.005| 10    | 0.433| 8     | 0.397| 9     | 0.016| 7     | 0.019| 9     | 0.347| 10    | 0.372|
|               | ≤25        | 13                  | 12    |       | 11    | 0.268| 9     | 0.400| 9     | 0.008| 7     | 0.009| 8     | 0.570| 10    | 0.327|
| GP73(ng/mL)   | >150       | 13                  | 0.004| 13    | 0.023| 14    | 0.269| 14    | 0.012| 13    | 0.006| 12    | 0.908| 9     | 0.569|
|               | ≤150       | 8                   | 9     |       | 8     | 0.269| 8     | 0.269| 7     | 0.006| 9     | 0.006| 7     | 0.713| 3     | 0.048|
| ALB(g/L)      | <35        | 10                  | 0.861| 11    | 0.547| 7     | 0.601| 12    | 0.384| 9     | 0.591| 12    | 0.713| 3     | 0.048|
|               | ≥35        | 9                   | 12    |       | 10    | 12    | 8     | 12    | 8     | 14    | 11    |       |       |       |       |
| TBIL(μmol/L)  | >19        | 11                  | 0.205| 12    | 0.048| 7     | 0.112| 13    | 0.322| 8     | 0.755| 29    | 0.008| 11    | 0.504|
|               | ≤19        | 9                   | 9     |       | 10    | 11    | 9     | 11    | 6     | 6     | 9     |       |       |       |       |
| ALT(U/L)      | >40        | 12                  | 0.022| 11    | 0.205| 9     | 0.125| 16    | 0.134| 10    | 0.589| 9     | 0.658| 10    | 0.270|
|               | ≤40        | 8                   | 11    |       | 8     | 10    | 7     | 12    |       |       |       |       |       |       |       |       |
cryoablation, but they had not obvious values in RFS prediction in other therapeutic methods.

There are still some limitations need to be taken into account in this study. We used retrospective RWD for analysis; though RWD can reflect the more realistic values, the results will be affected by various confounding factors and produce lower credibility compared with trial data. Moreover, we enrolled 104 patients in OS analysis, but only 15 of them were verified dead by electronic medical records. This proportion is lower than the mortality rate of HCC reported in literatures, because the final outcomes in most records were not available due to ethical issues.

In conclusion, our study demonstrates that three tumor biomarkers, including AFP, AFP-L3, and GP73, can be used as prognostic factors for predicting the recurrence of HCC, but liver function tests seem to have better survival prediction values. GP73 can act as a promising prognostic indicator for HCC, particularly in early-stage HCC. However, larger-scale prospective studies with multicenter are still needed to further verify our findings.

ACKNOWLEDGMENTS

This work was supported by grants from National key S&T Special Projects in China (2017ZX10302021-001-006) and Capital Characteristic Clinic Project in China (Z171100001017180).

CONFLICT OF INTEREST

The authors declare no competing financial interests.

DATE AVAILABILITY STATEMENT

The data used to support the findings of this study are available from the corresponding author upon request.

ORCID

Aixia Liu https://orcid.org/0000-0001-8017-055X

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Wang CY, Li SC. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: a single center 14 years experience from China. Medicine (Baltimore). 2019;98(4):e14070.
3. Shinu C, Subir S. Hepatocellular carcinoma: a life-threatening disease. Biomed Pharmacother. 2016;84:1679-1688.
4. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200-207.
5. Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2014;20(12):3112-3124.
6. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380.
7. Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev. 2014;15(4):1539-1544.
8. Zhang XF, Yin ZF, Wang K, Zhang QZ, Qian HH, Shi LH. Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance. Hepatobiliary Pancreat Dis Int. 2012;11(6):618-623.
9. Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One. 2014;9(1):e87011.
10. Meguro M, Mizuguchi T, Nishidate T, et al. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol. 2015;21(16):4933-4945.
11. Chinese Medical Association[Corporate Author]. Guidelines for diagnosis and treatment of primary hepatocellular carcinoma. Chin Clin Oncol. 2011;16(10):929-946.
12. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association[Corporate Author]. The guidelines of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi. 2011;35(1):405-415.
13. Hepatology Branch, Infectious and Parasitology branch, Chinese Medical Association [Corporate Author]. Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi. 2004;38:210-215.
14. Wang X, Huang K, Zeng X, et al. Diagnostic and prognostic value of mRNA expression of phospholipase C β family genes in hepatitis B virus associated hepatocellular carcinoma. Oncol Rep. 2019;41(5):2855-2875. https://doi.org/10.3892/or.2019.7066. [Epub ahead of print].
15. Li H, Zhao X, Li C, Sheng C, Bai Z. Integrated analysis of IncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma. Cancer Manag Res. 2019;11:877-897. https://doi.org/10.2147/CMAR.S186561. eCollection 2019.
16. Chen J, Yu Y, Xue C, et al. Low microRNA-139 expression associates with poor prognosis in patients with tumors: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2019;18(4):321-331. https://doi.org/10.1016/j.hbpd.2018.09.016.
17. He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res. 2019;12(11):1391-1400.
18. Ren Y, Fan X, Chen G, Zhou D, Lin H, Cai X. Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection. Med Clin (Bac). 2018;153(5):183-190.
19. Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97(51):e13696.
20. Kim SH, Moon DB, Kim WJ, et al. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5(6):461-469.
21. Montalvà EM, Cantos M, Boscá A, et al. Prognostic value of pretransplantation serum alpha-fetoprotein levels in hepatocellular carcinoma recurrence. Transplant Proc. 2016;48(9):2966-2968.
22. Li B, Li B, Guo T, et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget. 2017;8(46):80521-80530.
23. Li B, Li B, Guo T, et al. The clinical values of serum markers in the early prediction of hepatocellular carcinoma. Biomed Res Int. 2017;2017:5358615.
24. Cao Z, Li Z, Wang Y, et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat. 2017;24(1):57-65.
25. Liu L, Wang J, Feng J, et al. Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease. Sci Rep. 2018;8(1):16730.

26. Wei M, Xu Z, Pan X, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT. Sci Rep. 2019;9(1):1170.

27. Yao M, Wang L, You H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta. 2019;493:92-97.

28. Jing JS, Ye W, Jiang YK, et al. The value of GPC3 and GP73 in clinical diagnosis of hepatocellular carcinoma. Clin Lab. 2017;63(11):1903-1909.

29. Jiao C, Cui L, Piao J, Qi Y, Yu Z. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma. J Cancer Res Ther. 2018;14(6):1239-1244.